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Bisphosphonates (BPs) are an emerging class of drugs mostly used in the palliative care of cancer patients. We investigated the in vitro
activity of the most potent antiresorptive BP, zoledronic acid (ZOL), on the growth and survival of three human pancreatic cancer
(PC) cell lines (BxPC-3, CFPAC-1 and PANC-1). Pancreatic cancer frequently has a dysregulated p21
ras pathway and therefore
appears to be a suitable target for BPs that interfere with the prenylation of small GTP-binding proteins such as p21
ras. We found that
ZOL induces growth inhibition (IC50:10–50mM) and apoptotic death of PC cells. The proapoptotic effect was correlated to cleavage/
activation of caspase-9 and poly(ADP)-ribose polymerase, but not of caspase-3. Moreover, we studied the p21
ras signalling in cells
exposed to ZOL and detected a reduction of p21
ras and Raf-1 content and functional downregulation of the terminal enzyme ERK/
MAPkinase and of the pKB/Akt survival pathway. Finally, we observed that ZOL induces significant cytoskeletal rearrangements. In
conclusion, we demonstrated that ZOL induces growth inhibition and apoptosis on PC cells and interferes with growth and survival
pathways downstream to p21
ras. These findings might be relevant for expanding application of BPs in cancer treatment.
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Cancer of the exocrine pancreas is the fourth leading cause of
cancer-related deaths in both men and women (Fernandez et al,
1994). Even if advances in surgical techniques, radiation and
chemotherapy have provided significant improvements in the
overall survival and on the quality of life, fewer than 5% of
pancreatic cancer (PC) patients survive 5 years after diagnosis
(Parker et al, 1996). Therefore, it is not surprising that PC is a
serious health problem. Thus, there is a great demand for new and
more effective therapeutic strategies for the treatment of this
disease. Recent studies on pancreatic tumour tissues and cell lines
have shown that multiple subsets of genes undergo activation or
inactivation during development and progression of disease
(Hilgers and Kern, 1999). Specific point mutations at codon 12
of the K-ras oncogene are detected in 75–90% of PC specimens
and constitute the most common genetic changes in PC
(Almoguera et al, 1988). The mutated K-ras protein is not able
to convert GTP to GDP, resulting in constitutively active GTP-
bound species and constitutive activation of cell proliferative
signals. It is therefore conceivable that the pancreatic carcinoge-
netic process and/or the maintenance of the transformed
phenotype strongly rely on the dysregulated activity of the
p21
ras-mediated signalling. The inhibition of p21
ras signalling has
therefore been postulated as a possible target for anticancer
therapy and might be specifically suitable for the treatment of PC.
Bisphosphonates (BPs), the most effective and widely used class
of drugs in the treatment of metabolic bone disorders, including
tumour-associated bone disease, are capable of inhibiting p21
ras
signalling (Luckman et al, 1998; Green, 2001). Therefore, the
extensive evaluation of these compounds, and particularly the
study of the recently available and more potent nitrogen-contain-
ing BPs, may suggest expanding applications of these drugs and
warrant further investigation. It is well known that BPs are
compounds that strongly bind to hydroxyapatite crystals and
accumulate in mineralised bone (Jung et al, 1973). Bispho-
sphonates, which are specifically internalised into osteoclasts
(Sato et al, 1991), lead to inhibition of cell function because of
changes in the cytoskeleton and loss of the ruffled border (Carano
et al, 1990), as well as apoptosis (Hughes et al, 1995). Third-
generation, nitrogen-containing BPs, such as zoledronic acid
(ZOL) (Green et al, 1994), inhibit farnesyldiphosphate (FPP)
synthase, an enzyme involved in the mevalonate pathway (Luck-
man et al, 1998; Benford et al, 1999), preventing post-translational
events of prenylation of small GTP-binding proteins such as p21
ras,
Rab, Rho, Rac and cdc42 (Luckman et al, 1998), which are required
for a variety of biological functions including signal transduction
and cell adhesion.
In addition to the potent antiresorptive effects of nitrogen-
containing BPs, recent reports have also shown that these
compounds induce antiproliferative and apoptotic effects in
multiple myeloma cells in vitro (Shipman et al, 1997; Aparicio
et al, 1998), may synergise with chemotherapeutic or biological
agents (Tassone et al, 2000, 2002), and may offer clinical benefits
(Dhodapkar et al, 1998; Berenson et al, 1998). A direct effect
induced by BPs has also been demonstrated on tumour cells of
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snonhaematopoietic origin. Bisphosphonates induce inhibition of
adhesion of breast and prostate cancer cells to bone matrix (Van
Der et al, 1996; Boissier et al, 1997). In a mouse model of breast
cancer, BPs inhibited the progression and the development of bone
metastasis (Sasaki et al, 1995). Other studies have also suggested
that BPs may interfere with the growth and survival of metastatic
cancer cells in bone (Pelger et al, 1998). More recently, a variety of
studies have focused on the direct effect of BPs on growth and
survival of cancer cells from solid tumours. ZOL induces a
significant reduction of cell viability, increases apoptotic cell
death and downregulation of bcl-2 protein, p21
ras delocalisation
from the cell membrane and proteolytic cleavage of PARP,
indicating direct antitumour effects on human breast cancer cells
(Senaratne et al, 2000; Senaratne et al, 2002). In prostate cancer
cells, ZOL has shown a remarkable inhibitory effect on cell
proliferation by induction of cell death and/or cytostasis in vitro
(Lee et al, 2001).
In this scenario, since there have been no studies addressing the
possibility of a direct effect of BPs on growth and survival of
human PC cells, we studied the activity of the most potent BP,
ZOL, on a panel of different human PC cell lines (BxPC-3, CFPAC-
1 and PANC-1). We have additionally studied whether the
nitrogen-containing ZOL might induce effects on the p21
ras/raf1/
MEK1/ERK and on the pkB/Akt pathways, and if apoptosis should
be related to caspase-9/-3 and PARP cleavage/activation in these
cancer cells.
MATERIALS AND METHODS
Cell cultures and reagents
The PC cell lines BxPC-3, CFPAC-1 and PANC-1 were purchased
from the American Type Culture Collection (Rockville, MD, USA).
BxPC-3 and CFPAC-1 are adherent human pancreatic adenocarci-
noma cell lines that were grown in RPMI 1640 and Iscove’s
modified Dulbecco’s media, respectively. PANC-1 is a human
epithelioid pancreas carcinoma cell line that was grown in
Dulbecco’s modified Eagle’s medium (DMEM). All media were
supplemented with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine, 100mgml
1 streptomycin and 100Uml
1 penicillin.
All PC cell lines were cultured at a constant temperature of 371Ci n
a humidified atmosphere of 5% carbon dioxide (CO2). The
bisphosphonic acid monohydrate ZOL, 1-hydroxy-2-[(1H-imidazol-
1-yl) ethylidene], a third-generation BP, was kindly provided as the
hydrated disodium salt by Novartis Pharma AG (Basel, Switzer-
land). The neutralised sodium salt of ZOL was dissolved in sterile
ddH2O and used at a final concentration in a range of 1–100mM.
Stock solutions of ZOL were aliquoted and kept at 201C for long-
term storage. Anti-caspase-9/-3 and anti-PARP MAbs were
purchased from New England Biolabs (Beverly, CA, USA). Protein
sepharose was purchased from Sigma (St Louis, MO, USA). Rabbit
antisera raised against raf-1 C-12, bactin, ERK-1 K-23 and ERK-2
MAb C-14 were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-pan-ras MAb clone 10 was purchased from
Calbiochem (San Diego, CA, USA). Anti-Akt MAbs, GSK3b fusion
protein and anti-pGSK3b MAbs were all from Cell Signaling Tech.
(Beverly, MA, USA).
Cell proliferation assay
Analysis of cell proliferation was performed on PC cells in the
presence of increasing concentrations of ZOL by the MTT assay.
Briefly, PC cells (310
4well
1) were seeded in 96-well plates in
serum-containing media and allowed to attach for 24h. The
medium was then removed and replaced with new medium
containing ZOL at different concentrations. Cells were incubated
under these conditions for a time course spanning 72h. Then cells
were incubated with 10mlwell
1 of thiazolyl blue (MTT, 5mgml
1,
Sigma) for 1h at 371C. After incubation, 100ml of 0.04 N HCl in
isopropanol was added into each well and the absorbance was
measured at a wavelength of 620nm in a microplate reader. A
value of 100% was assigned to untreated control cultures, and the
IC50 was defined as the concentration of drug that reduced the
number of viable cells to 50% of the control cultures after 72h of
exposure.
Flow cytometric analysis of apoptosis
Apoptotic cell death was analysed by Annexin-V–FITC staining
and by propidium iodide (PI) detection systems. Annexin-V–FITC
binds to phosphatidylserine residues, which are translocated from
the inner to the outer leaflet of the plasma membrane during the
early stages of apoptosis. Labelling of apoptotic cells was
performed using an Annexin-V kit (MedSystems Diagnostics,
Vienna, Austria). Briefly, cells were incubated with Annexin-V–
FITC in a binding buffer (provided by the manufacturer) for
10min at room temperature, washed and resuspended in the same
buffer as described by the manufacturer. Analysis of apoptotic cells
was performed by flow cytometry (FACScan, Becton Dickinson).
Propidium iodide analysis of apoptosis was performed using a
commercial kit (MedSystems Diagnostics, Vienna, Austria). The
cells were washed in PBS, resuspended in 190ml of prediluted
binding buffer (1:4) and incubated for 10min with 10ml of the
20mgml
1 propidium iodide stock solution, and then the
apoptotic cells were analysed by FACScan flow cytometer. For
each sample, 210
4 events were acquired. Analysis was carried
out by triplicate determination on at least three separate
experiments. Induction of apoptotic cell death was further
performed in the presence or absence of specific caspase
inhibitors: VAD-fmk(-fluoromethylketone) which is a caspase-9
inhibitor, VEID-fmk which is specific for caspase-6 and DEVD-
fmk which is a caspase-3 inhibitor.
Immunoblotting for p21
ras, raf-1, ERK, pERK, caspase-9/-3,
Akt
For extract preparation, the cells were washed twice with ice-cold
PBS/BSA, scraped and centrifuged for 30min at 41C in 1ml of lysis
buffer (1% Triton, 0.5% sodium deoxycholate, 0.1N NaCl, 1mM
EDTA, pH 7.5, 10mM Na2HPO4, pH 7.4, 10mM phenylmethylsul-
phonyl fluoride (PMSF), 25mM benzamidin, 1mM leupeptin,
0.025Uml
1 aprotinin). Equal amounts of cell proteins were
separated by SDS–PAGE. The proteins on the gels were
electrotransferred to nitrocellulose and reacted with the different
MAbs. Nitrocellulose filters were subsequently exposed to HRP-
conjugated secondary antibodies. Finally, the film was washed with
PBS/0.05% Tween 20 and immunoreactive proteins were detected
by the ECL, chemiluminescence technique (Amersham, Uppsala,
Sweden).
Analysis of pKB/Akt activity
Akt assay was performed using reagents supplied as a kit obtained
from Cell Signaling Technology Inc. (Cell Signaling Tech., Beverly,
MA, USA). Briefly, 10
6 PC cells were lysed in a buffer containig
20mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA, 1%
Triton X-100, 2.5mM sodium PPi,1m M b-glycerophosphate, 1mM
Na3VO4 and 1mgml
1 leupeptin. Equal amounts of lysed proteins
were immunoprecipitated overnight with sepharose-coupled anti-
Akt antibodies at 41C. Immunocomplexes were washed four times
with lysis buffer and twice with kinase buffer composed of 25mM
Tris (pH 7.5), 5mM b-glycerophosphate, 2mM DTT, 0.1mM
Na3VO4 and 10mM MgCl2. Immune complexes were resuspended
in 40ml of kinase buffer, supplemented with 200mM ATP and 1mg
of GSK-3a/b fusion protein, and incubated at 301C for 30min. The
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skinase reaction was stopped by the addition of 20mlo f3 SDS
sample buffer. Samples (20ml) were analysed by Western blotting
with antiphospho-GSK-3a/b antibody after PAGE separation.
Immunofluorescence detection of actin
Pancreatic cancer cells were seeded onto 35-mm culture dishes on
sterile coverslips and allowed to attach for 24h. Subsequently, the
cells were incubated for 48h in the presence of ZOL (15mM). The
medium was then removed, cells washed with PBS and fixed with
1ml Cytofix/cytoperm (Pharmigen, CA, USA) for 45min at 41C.
Subsequently, the fixation buffer was removed and cells washed
with 1ml of 1 washing buffer. For visualisation of filamentous
actin, the cells were exposed to rhodamine–phalloidin
(100mgml
1) (Sigma) for 10min at 41C and washed with washing
buffer. After final washes, coverslips were mounted on the dishes
using a 50% solution of glycerol in PBS. The cells were examined
under a LEICA TCS SP2 confocal microscope.
Statistical analysis
Results are expressed as mean 7s.e. The statistical significance of
differences between the experimental points was analysed
using the t-test; differences were considered significant when
Po0.05.
RESULTS
Zoledronic acid induces antiproliferative effects on PC
cells
The effect of ZOL on BxPC-3, CFPAC and PANC-1 PC cells
was investigated in vitro using the MTT assay. Treatment with ZOL
(1–100mM) produced a dose-dependent reduction of cell growth
after 72h of treatment (Figure 1A) and the IC50 was calculated in a
range of 10–50mM (Figure 1B). Figure 1C and D show the
morphological changes of cultured PC cells after 72h exposure to
ZOL (50mM). Untreated cells (Figure 1C) were flat and well spread,
but exposure to the drug (Figure 1D) resulted in significant
antiproliferative effects, retraction of cells from the substratum,
rounding up and loss of contact between neighbouring cells.
Altogether, these findings indicate that ZOL exerts growth
inhibitory activity on PC cells.
Zoledronic acid induces apoptotic death of PC cells
To clarify the mechanisms of ZOL-induced growth inhibition, we
performed apoptotic assays on PC cells exposed to this compound.
Activation of apoptosis was detected by Annexin-V staining, which
is early expressed on the outer side of the cell membrane only
when apoptosis is triggered and by PI which directly measures
fragmented DNA. Figure 2 shows the apoptotic death of BxPC-3,
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Figure 1 Zoledronic acid inhibits the growth of PC cells. (A) The cell lines BxPC-3, CFPAC-1 and PANC-1 (310
4ml
1) were seeded in 96-well plates
and incubated for 24h. After 24h, medium was removed and replaced with medium containing increasing concentrations of ZOL (1–100mM). After 72h of
incubation, cell proliferation was determined by the MTT assay. A value of 100% was assigned to untreated control cultures, and the antiproliferative effects
of ZOL were calculated as percentage of residual growth. Each point is the mean value of at least four replicate experiments 7s.e. (B) The IC50 drug
concentration for each cell line was measured by a logarithmic interpolate curve on the percentage of residual growth at each concentration point (C and
D) Morphological changes induced in cell cultures after 72h exposure to ZOL. Analysis was performed by inverted phase-contrast microscopy.
(C) Untreated cultures; (D) treated cultures with ZOL (50mM).
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sCFPAC-1 and PANC-1 cells after 6, 12 and 24h exposure to 50mM
ZOL. Apoptotic cell death was detected in 35–90% of treated PC
cells, suggesting a significant role of apoptotic death in the in vitro
activity of ZOL. Notably, induction of the apoptosis was
independent from the length of ZOL exposure. After 6–12h from
the beginning of ZOL exposure, Annexin-V staining was equally
detected in cells treated by a 30–180min pulse as compared with
cells treated with continuous drug exposure, suggesting that
induction of the apoptotic process is an early event in pancreatic
cells exposed to ZOL. DNA fragmentation demonstrated by the PI
experiment became evident after 24h and again was independent
from the length of exposure (pulse vs continuous).
Caspase- and PARP-dependency of ZOL-induced apoptosis
in PC cells
We investigated the molecular mechanisms of ZOL-induced
apoptosis in these cells. We found that exposure of PC cells to
ZOL increased PARP cleavage, a key enzyme in the apoptotic
cascade, as demonstrated by Western blot analysis, which showed
a higher expression of the 116kDa proenzyme and the appearance
of an 89kDa cleavage product in treated cells. The maximal effect
was detected after 72h of ZOL exposure (Figure 3A). We also
found that caspase-9 was cleaved/activated after cell exposure to
the drug, while no effect was detected on caspase-3. These data
were confirmed by the use of specific caspase inhibitors. We
demonstrated that the caspase-9 inhibitor Z-VAD and the specific
caspase-6 inhibitor VEID almost completely prevented apoptotic
death of PC cells, while the DEVD caspase-3 inhibitor only slightly
affected apoptosis induced by ZOL, as detected by flow cytometric
analysis of Annexin-V staining (Figure 3B). These findings suggest
that apoptosis induced by ZOL on human PC cells is caspase-9-,
caspase-6- and PARP-dependent, but caspase-3-independent.
Zoledronic acid inhibits the p21
ras/Raf1/MEK/ERK1-2
mitogenic and pKB/Akt antiapoptotic pathways in PC cells
In order to investigate the molecular mechanism of ZOL-induced
growth inhibitory activity, we analysed whether the drug would
affect the function of the ras/raf1/MEK/ERK1-2 pathway. We
observed a strong decrease of the intracellular content of p21
ras
and of its substrate Raf-1 as evaluated by Western blotting (Figure
4A and B). In fact, 48h treatment with 50mM ZOL induced a two-
to-three-fold reduction of the expression of the two signalling
components (Figure 4A and B). Subsequently, we studied the
effects of ZOL on the activity of ERK1-2, the terminal enzyme of
the ras/raf-1 antiapoptotic and survival pathway. We found a
strong decrease of the activity of the two enzymes, as demonstrated
by the immunodetection of the phosphorylated forms of ERK1-2
(Figure 4E). On the other hand, no changes in the intracellular
levels of ERK1-2 were found in the ZOL-treated PC cells
(Figure 4D). These data suggest a significant inhibition of the
signalling activity of this mitogenic and survival pathway. Another
important and ras-dependent survival pathway of human cancer
cells is mediated by the activation of the intracellular kinase pKB/
Akt. Therefore, we also studied the effects of ZOL on Akt activity.
We observed a significant impairment of pKB/Akt activity in cells
exposed to ZOL as demonstrated by reduced phosphorylation of
Figure 2 (A) Apoptotic effects induced by ZOL on CFPAC-1, PANC-1, BxPC-3 PC cancer cells. The analysis of apoptosis was performed after exposure
to 50mM of ZOL by flow cytometric detection of Annexin-V immunostaining. Cells were pulse exposed for 30, 60 and 180min or continuously exposed to
the drug. The PI method was used when apoptosis was evaluated 24h after beginning treatment. Data are expressed as the mean value of at least four
replicate experiments 7s.e. (B) Flow cytometric profiles from a representative experiment performed on CFPAC-1 cells. The percentage of apoptotic
stained cells (%) is indicated in each quadrant.
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sthe GSK3a/b fusion protein induced by the immunoprecipitated
Akt (Figure 4F). We conclude that ZOL interferes with signalling
pathways, which mediate proliferative stimuli and protect tumour
cells from triggering apoptosis.
Zoledronic acid induces actin cytoskeletal reorganisation
in PC cells
Finally, we studied whether the morphological changes induced in
PC cells after exposure to ZOL occurred together with cytoskeletal
reorganisation, which is considered to antagonise cell migration
and invasion (Nobes and Hall, 1995). After 48h exposure to ZOL
(15mM), we observed reorganisation of the cytoskeleton and
cortical actin polymerisation as judged by confocal microscopy
detection of phalloidin-stained actin filaments. At these concen-
trations and exposure time, ZOL did not induce increased
apoptotic death as compared with untreated cells. Figure 5 shows
cytoskeletal rearrangements into cortical rings after the treatment.
These findings suggest that the drug may trigger apoptotic death of
PC cells, at least in part by interfering with cytoskeletal integrity.
DISCUSSION
In this study, we have demonstrated that the most potent
antiresorptive nitrogen-containing BP ZOL causes antiproliferative
Figure 3 Role of caspase-9/-3 and PARP in apoptotic cell death induced
by ZOL. (A) Detection of caspase-9/-3 and PARP in PC cells after ZOL
treatment. Western blotting analysis was performed on protein extracts
from solubilized whole cell pellets from BxPC-3 and PANC1 PC cell lines
after 48h exposure to ZOL (50mM) demonstrating abundant cleaved
species of both caspase-9 and PARP in lysates for drug-exposed cells, while
caspase-3 remained almost completely uncleaved. The experiments were
performed at least three times and the results were always similar. (B)
Apoptotic effects induced by ZOL in the presence of caspase inhibitors.
Analysis was performed by flow cytometric immunodetection of Annexin-
V staining on BxPC-3 cells after 48h exposure to ZOL (50mM). VAD is a
caspase-9 inhibitor, VEID is a specific caspase-6 inhibitor and DEVD is a
caspase-3 inhibitor. Pretreatment with 15mM VAD and 15mM VEID
significantly antagonised ZOL-induced apoptosis (Po0.005).
Figure 4 Effects of ZOL treatment on p21
ras/Raf-1/MEK1/ERK signalling
and PK-B/Akt pathways in PC cells. Western blotting analysis of p21
ras (A),
raf-1 (B), Erk-1/2 (D) and pErk (E). The immunoblotting shows
downregulation of p21
ras (A) and raf-1 (B) levels after 48h of
exposure to 50mM ZOL. While no significant effects were detected on
Erk-1/2 expression after exposure of cells to the drug (D), the active
phosphorylated Erk-1/2 (recognised by an anti-pERK Mab) levels
were greatly reduced in ZOL-treated cells (E). (F and G) Akt
expression and functional analysis in BxPC-3, PANC-1 and CFPAC-1
pancreatic adenocarcinoma cells. For detection of Akt activity, immuno-
precipitation was performed from cell lysates with anti-Akt antibody, and an
in vitro kinase assay was performed using GSK3a/b as a substrate, followed
by Western blotting analysis with antiphospho-GSK3a/b. GSK3a/b
phosphorylation by immunoprecipitated Akt was downregulated after
48h treatment of PC cells with 50mM ZOL (F), whereas the Akt protein
levels remained unmodified. The experiments were performed at
least three times and the results were always similar. CTR: untreated cells;
ZOL: ZOL-treated cells.
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seffects, perturbation of the p21
ras/Raf1/MEK/ERK1-2 mitogenic
pathway and pKB/Akt survival signalling, and also induces
apoptotic death of human PC cells in vitro. We have also shown
that the apoptotic events induced by the drug directly involve
activation of caspase-9, caspase-6 and PARP. The present study
provides the first evidence that a nitrogen-containing BP can
directly interfere with intracellular mitogenic and survival path-
ways downstream to p21
ras and produce antitumour effects in
cultured PC cells.
Bisphosphonates are an emerging class of drugs mostly used in
the palliative care of cancer patients. These compounds are specific
inhibitors of osteoclastic activity and may significantly reduce
skeletal complications, thereby sustaining the quality of life of
cancer patients. There is a growing interest in the possibility that
BPs may also improve survival in these patients. Several properties
of BPs have been recently highlighted. Experimental findings
suggest that these drugs may directly act on cancer cells, either by
inhibiting tumour cell invasion or adhesion to bone matrix or by
inducing growth inhibitory and/or apoptotic cell death. This
proapoptotic ability of BPs has been strongly correlated with the
specific antiresorptive potency of each compound. Specifically, it
has been demonstrated that ZOL has a direct effect on human
multiple myeloma (Shipman et al, 1997), breast cancer (Senaratne
et al, 2000), prostate cancer (Lee et al, 2001) and melanoma cells
(Riebeling et al, 2002).
We found that ZOL induces significant antiproliferative effects
in a range of 10–50mM. These data agree with most other in vitro
studies showing maximal growth inhibitory effects of BPs at doses
higher than what is persistently achievable in the serum of patients
after treatment. In fact, it has been shown that infusion of
Pamidronate, which is a less potent antiresorptive BP commonly
used in palliative treatments, gives serum concentrations B10-fold
lower (0.5–8mM) (Daley-Yates et al, 1991; Oiso et al, 1994;
Berenson et al, 1997).
It is well known that BPs have a rapid clearance from the blood
stream and therefore only effects induced by short-term exposure
have a clinical relevance for extra bone antitumour activity. We
have indeed that induction of apoptotic death in PC cells occurs
after only 30min pulse exposure and does not require continuous
drug exposure. We think therefore that this latter finding increases
the potential translational fall-out of this study. Moreover, we
consider of interest that PC has been reported to metastasize to
bone in approximately 15% of the cases. The low rate of bone
involvment is not unexpected, because only with the recent
improvements in diagnosis and treatment PC patients begin to
survive long enough to reach the stage of disease most associated
with distant skeletal lesions. Even if it has not been stated which
bone sites may be specifically involved in metastatic spread, it has
been suggested that PC metastasises to bone in a pattern that
predominantly favours the pelvic girdle (Lyons et al, 2001). These
lesions may heavily affect the quality of life of advanced cancer
patients and overall survival. Therefore, our data strengthen the
rationale for the use of these drugs in a palliative treatment of
skeletal metastatic disease. It has however to be underlined that
palliative effects on the metastasis at the bone site do not
necessarily involve direct antitumour activity.
The molecular bases of the BP antitumour activity remain to be
elucidated. However, one possible mechanism is based on the
ability of BPs to inhibit some of the enzymes involved in the
pathway for cholesterol synthesis. Relevant to our study,
dysregulation of p21
ras activity appears to be a critical event for
the onset of PC. We have shown that ZOL interferes with the
p21
ras/raf-1/MEK1/ERK and pKB/akt signalling cascades, as p21
ras
and Raf-1 contents were clearly reduced in PC cells, and the active
phosphorylated species of ERK1-2-, and pKB/akt-mediated phos-
phorylation of GSKa/b were strongly downregulated in cells
exposed to the drug. These data appear to be of specific interest
considering the widely described growth promoting and anti-
apoptotic activity of the two p21
ras-dependent raf-1/MEK1/ERK
and pKB/Akt pathways, and our study provides, at our knowledge,
the first evidence that ZOL affects the intracellular signalling
pathway downstream to p21
ras. Moreover, it has been demon-
strated that Akt directly inhibits caspase-9 activity by phosphor-
ylation and, intriguingly, we demonstrated that in our
experimental model ZOL-induced apoptosis is caspase-9-depen-
dent (Fujita et al, 1999; Zhou et al, 2000). In fact, we demonstrated
that, in parallel with the antiproliferative effects mediated by the
drug, ZOL also induces apoptotic cell death in PC cells. Cell death
by an apoptotic process is a well-described phenomenon that is
associated with multiple molecular events. The caspase family of
cysteine proteases are central participants in apoptotic cell death.
Recent studies have highlighted the potential role of caspase-9 as a
Figure 5 Analysis of cytoskeletal reorganisation by confocal microscopy on PANC-1 PC cells after 48h exposure to ZOL (15mM). The figure shows actin
architecture rearrangements in cortical rings. The cells were examined under a confocal microscope at a magnification of 100. The experiments were
performed at least three times and the results were always similar.
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sselective target for anticancer treatment. It is also believed that
chemotherapeutic agent-induced apoptosis is predominantly
accomplished by activation of the mitochondrial pathway (Wu
and Ding, 2002). In fact, blockade of caspase-9 decreases
chemotherapeutic agent-induced mitocondrial-dependent apopto-
sis. In this context our observations are in agreement with other
studies which reported that ZOL-mediated apoptosis is associated
with cytochrome c release and consequent caspase activation
(Senaratne et al, 2002). Caspase-3 is considered to be involved in
the execution phase of apoptosis, when proteolysis of intracellular
substrates is a major event. It has been shown that BP-induced
osteoclast apoptosis is dependent on caspase-3 activation since cell
death is prevented by caspase-3 inhibitors, thereby suggesting the
key role of these proteases in apoptotic cell death induced by these
drugs (Benford et al, 2001). Caspase-3 has also been involved in
apoptotic death of breast cancer cells exposed to ZOL (Senaratne
et al, 2002). In our study however, we have been unable to find a
specific role for caspase-3, which is not cleaved/activated, and
apoptosis was only slightly antagonised by selective caspase-3
inhibition. Our observations are in accordance with others who
found no correlation between the amount of processing of caspase-
9 and effector caspases in human pancreatic carcinoma (Gerhard
et al, 2002). We can therefore hypothesise that in ZOL-exposed PC
cells, a caspase-9- and caspase-6-dependent and caspase-3-
independent pathway is operative, while in other tumour cell
systems, as well as in normal osteoclast cells, execution of
apoptosis induced by ZOL may occur by a caspase-3-dependent
mechanism. The possible identification of tissue-specific execu-
tioners of apoptosis might be ideal subjects of investigation, and
may have the advantage of enhancing selectivity in therapeutical
intervention.
Activation of caspases during cell death is commonly associated
with characteristic intracellular changes of in vitro cultured cells,
including loss of adhesion, actin-cytoskeletal structural reorgani-
sation into cortical rings, cell rounding and contracting, and
generation of apoptotic bodies. A role for caspase-mediated
proteolysis of structural and adhesion proteins has been suggested
in the morphological changes that characterise apoptotic cell
death. After the initial phase of contraction and blebbing, caspase-
mediated cleavage of actin monomers probably induces disas-
sembly of actin filaments (Mashima et al, 1997; McCarthy et al,
1997). We found that after 48h of low concentration ZOL
treatment, significant actin-cytoskeletal reorganization occurs in
PC cells as demonstrated by actin staining. These modifications
indicate that ZOL induces actin rearrangements into cortical rings
and that these events may drive the cells to the apoptotic process.
This specific effect indicates the intriguing possibility of positive
interactions of BPs with drugs that interfere with actin polymer-
isation and depolymerisation such as taxoid or vinca alkaloid
agents. A synergistic effect of ZOL with paclitaxel has in fact been
demonstrated in human breast cancer (Jagdev et al, 2001). Recent
reports have also highlighted the role of signal transduction
pathways controlled by the Rho family of small GTPases in
regulating the architecture of the actin cytoskeleton and the
morphological changes during apoptotic cell death (Coleman and
Olson, 2002). An intriguing preliminary finding is that the small
GTP-binding protein RAC, functionally related to cytoskeletal
organisation, discloses enhanced (10-fold) expression in ZOL-
exposed cancer cells as detected by Western blot analysis (data not
shown). Based on these findings, further studies are presently in
progress in order to understand the functional significance of these
observations.
In conclusion, we have demonstrated that PC cells are highly
sensitive to ZOL-induced growth perturbation and induction of
apoptosis, which is caspase-9- caspase-6- and PARP-dependent.
Moreover, our experimental findings suggest that inhibition of
p21
ras/Raf-1/MEK1/ERK signalling as well as PK-B/Akt inhibition
might be relevant for the antitumour effects of ZOL. Although we
have been capable of demonstrating that a short-term exposure is
enough for activation of apoptosis, we think that a pharmacoki-
netic profile more relevant to the extra-bone antitumour effects of
ZOL should be derived and might involve entrapping of BPs in
lysosomes. An additional topic of current investigation is BP
combination with cytotoxic drugs or selective signal transduction
inhibitors.
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